Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. View (RXRX) real-time stock price, chart, news, analysis, analyst reviews and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback